


by Olivia Grant | Jan 10, 2022 | Blog
New FDA Guidance to Support Ultra-Rare Disease Drug Development by Dr. Amanda Beaster, Senior Manager of Regulatory Strategy Antisense oligonucleotide (ASO) drug products target a specific sense mRNA to modulate gene expression in living cells and have been...by Olivia Grant | Oct 28, 2021 | News
Praxis Bioresearch Seeks Regulatory Strategy Support from MMS Holdings to Develop Therapeutics for Alzheimer’s Disease SACRAMENTO, Calif. (October 28, 2021) – MMS Holdings (MMS) – a data-focused CRO – provided regulatory strategy support to Praxis...Cookie | Duration | Description |
---|---|---|
cookielawinfo-checbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |